JP6480847B2 - ロキソプロフェン含有外用剤組成物 - Google Patents
ロキソプロフェン含有外用剤組成物 Download PDFInfo
- Publication number
- JP6480847B2 JP6480847B2 JP2015202787A JP2015202787A JP6480847B2 JP 6480847 B2 JP6480847 B2 JP 6480847B2 JP 2015202787 A JP2015202787 A JP 2015202787A JP 2015202787 A JP2015202787 A JP 2015202787A JP 6480847 B2 JP6480847 B2 JP 6480847B2
- Authority
- JP
- Japan
- Prior art keywords
- loxoprofen
- external preparation
- propylene glycol
- fatty acid
- preparation composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002373 loxoprofen Drugs 0.000 title claims description 43
- 238000002360 preparation method Methods 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 title claims description 24
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 title claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 61
- -1 propylene glycol fatty acid ester Chemical class 0.000 claims description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 claims description 6
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 47
- 239000006071 cream Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229960004211 loxoprofen sodium dihydrate Drugs 0.000 description 8
- 231100000245 skin permeability Toxicity 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- COPFWAGBXIWZNK-UHFFFAOYSA-N 2,3-bis(6-methylheptanoyloxy)propyl 6-methylheptanoate Chemical compound CC(C)CCCCC(=O)OCC(OC(=O)CCCCC(C)C)COC(=O)CCCCC(C)C COPFWAGBXIWZNK-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-M loxoprofen(1-) Chemical compound C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014210813 | 2014-10-15 | ||
| JP2014210813 | 2014-10-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016079180A JP2016079180A (ja) | 2016-05-16 |
| JP2016079180A5 JP2016079180A5 (enExample) | 2018-06-28 |
| JP6480847B2 true JP6480847B2 (ja) | 2019-03-13 |
Family
ID=55957675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015202787A Active JP6480847B2 (ja) | 2014-10-15 | 2015-10-14 | ロキソプロフェン含有外用剤組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6480847B2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018084295A (ja) * | 2016-11-24 | 2018-05-31 | 株式会社ユーテック | 水圧駆動システム |
| JP7515277B2 (ja) * | 2019-03-25 | 2024-07-12 | 第一三共ヘルスケア株式会社 | ロキソプロフェン配合皮膚外用剤 |
| JP2023018864A (ja) * | 2021-07-28 | 2023-02-09 | 第一三共ヘルスケア株式会社 | ロキソプロフェン含有外用塗布剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09316007A (ja) * | 1996-05-31 | 1997-12-09 | Advanced Sukin Res Kenkyusho:Kk | 局所適用組成物 |
| KR100228514B1 (ko) * | 1996-09-05 | 1999-11-01 | 한승수 | 비스테로이드성 소염진통제를 활성성분으로 하는 경피흡수제제의 제조방법 |
| JP4275751B2 (ja) * | 1996-12-27 | 2009-06-10 | 久光製薬株式会社 | 外用組成物 |
| JP2935113B1 (ja) * | 1998-09-24 | 1999-08-16 | 小林製薬株式会社 | インドメタシン経皮吸収剤 |
| JP4195178B2 (ja) * | 1999-11-10 | 2008-12-10 | 東興薬品工業株式会社 | 消炎鎮痛外用剤 |
| JP4526598B2 (ja) * | 2007-08-29 | 2010-08-18 | 祐徳薬品工業株式会社 | 乳化型外用剤およびその製造方法 |
| JP2009269900A (ja) * | 2008-04-07 | 2009-11-19 | Kao Corp | タイトジャンクション形成促進剤 |
| WO2010124175A1 (en) * | 2009-04-24 | 2010-10-28 | Johnson & Johnson Consumer Companies, Inc. | Stable topical compositions for 1,2,4-thiadiazole derivatives |
| JP5788256B2 (ja) * | 2010-07-29 | 2015-09-30 | 富士カプセル株式会社 | シームレスカプセル充填用組成物 |
| JP5356629B2 (ja) * | 2011-05-27 | 2013-12-04 | ロート製薬株式会社 | 外用組成物 |
-
2015
- 2015-10-14 JP JP2015202787A patent/JP6480847B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016079180A (ja) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5734479B2 (ja) | ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス | |
| KR102184245B1 (ko) | 케토프로펜 국소 조성물 | |
| JP7779642B2 (ja) | ロキソプロフェン配合皮膚用外用剤 | |
| CN104428003B (zh) | 双氯芬酸制剂 | |
| JP7557010B2 (ja) | ロキソプロフェン配合皮膚用外用剤 | |
| Baek et al. | Enhanced transdermal drug delivery of zaltoprofen using a novel formulation | |
| JP6456533B2 (ja) | ロキソプロフェン含有外用剤組成物 | |
| JP2015531374A5 (enExample) | ||
| JP2018135342A (ja) | 皮膚の病的状態を治療するための組成物及び方法 | |
| US11872199B2 (en) | Topical formulations of cyclooxygenase inhibitors and their use | |
| JP6480847B2 (ja) | ロキソプロフェン含有外用剤組成物 | |
| JP4195178B2 (ja) | 消炎鎮痛外用剤 | |
| JP2024163305A (ja) | ロキソプロフェン及び可溶化剤を含有する皮膚外用剤 | |
| JP7515277B2 (ja) | ロキソプロフェン配合皮膚外用剤 | |
| JP2015083563A (ja) | ロキソプロフェン配合皮膚外用液剤 | |
| ES2880437T3 (es) | Nuevas composiciones tópicas que comprenden ácido úsnico y su uso terapéutico | |
| JPH01121218A (ja) | 外用皮膚疾患治療クリーム剤 | |
| KR101894891B1 (ko) | 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형 | |
| JP6253495B2 (ja) | ロキソプロフェンを含有する外用剤組成物 | |
| JP2022111098A (ja) | ロキソプロフェン配合皮膚外用剤 | |
| JP6503626B2 (ja) | 医薬組成物 | |
| JP5980171B2 (ja) | アダパレン含有外用剤組成物 | |
| Ekka et al. | Preparation and evaluation of Diclofenac & Aceclofenac pain relieving gel | |
| JP2014208618A (ja) | 医薬液体組成物 | |
| CA3230189A1 (en) | Compositions and formulations for topical use of an akt inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180515 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180515 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190208 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6480847 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |